January 29, 2026

Register Now: TMS and Connectomics in Neurosurgery Symposium: Applications for Brain Mapping, Surgical Planning and Rehabilitation

Join us for a one-day, peer-focused symposium convening physicians and healthcare professionals experienced in transcranial magnetic stimulation (TMS) to connect, collaborate and advance its role in neurosurgery.

Baptist Health South Florida

January 23, 2026

Redefining Neuro-Ophthalmology

The eye-brain connection and the future of imaging

The Ophthalmologist

January 09, 2026

AAN Issues Guideline on Functional Seizures

Psychological interventions nearly double the odds of seizure freedom; benzodiazepines and antiseizure medications not recommended without co-occurring epilepsy

Conexiant

January 07, 2026

Periodontal Disease and ASCVD: Updated

AHA Scientific Statement examines the association between periodontal disease and atherosclerotic cardiovascular disease

Conexiant

November 30, 2025

Scientists Demonstrate the Tremendous Promise of AI and Machine Learning for Predicting Stroke And Other Neurological Disorders

Identifying acute stroke remains one of the toughest challenges facing emergency medicine and neurology. Traditional stroke alert systems register false positive results in up to two-thirds of cases, resulting in inefficient utilization of costly resources and delays in appropriate care for both stroke and non-stroke patients.

Mount Sinai New York

November 26, 2025

This Week’s Biopharma News: Texas Takes on BMS and Sanofi

This week’s news roundup reports on Texas’s claim against BMS and Sanofi, AstraZeneca’s Maryland investment, Novo Nordisk’s difficult semaglutide admission, and more.

The Medicine Maker

November 20, 2025

Vorasidenib in IDH1/2-Mutant Low-Grade Glioma

As reported in The Lancet Oncology by Cloughesy et al, vorasidenib was associated with improvement in some secondary and exploratory outcomes vs placebo in the phase III INDIGO trial in patients with ...

The ASCO Post

November 19, 2025

FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas

The MEK inhibitor was approved today for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. In September 2025, the FDA approved selumetinib capsules a...

The ASCO Post

November 13, 2025

Swallowing Safely: Evidence-Based Approaches to Tablets and Dysphagia

In stroke patients with dysphagia, the default practice of crushing tablets could increase residue, reduce efficacy, and raise aspiration risk. Researchers reveal how individualized FEES assessments can transform medication safety at the bedside.

The Medicine Maker